文献速递认知障碍与痴呆

磷酸二酯酶5抑制剂与勃起功能障碍男性阿尔茨海默病风险:一项队列研究

Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
PubMed 文献 · Neurology · 2024-02-07

基于英国IQVIA医学研究数据,纳入2000至2017年新诊断勃起功能障碍的≥40岁男性269,725例,中位随访5.1年期间1,119例新发阿尔茨海默病。启动磷酸二酯酶5抑制剂(PDE5I)与非使用相比,校正风险比HR 0.82(95%CI 0.72-0.93);处方21-50次者HR 0.56(95%CI 0.43-0.73),>50次者HR 0.65(95%CI 0.49-0.87)。作者认为需随机对照试验确认关联。

要点

  • PDE5I启动者较非使用者阿尔茨海默病风险降低,HR 0.82(95%CI 0.72-0.93)。
  • 处方21-50次者HR 0.56(95%CI 0.43-0.73),>50次者HR 0.65(95%CI 0.49-0.87)。
  • 3年滞后敏感性分析结果不同,HR 0.93(95%CI 0.80-1.08),未达统计学显著。

核心结论

  • 勃起功能障碍男性中,启动PDE5I与非使用相比与阿尔茨海默病风险降低相关,尤其在处方最频繁者中。
  • 主分析与敏感性分析的差异提示需探索最佳滞后时间。
  • 作者认为需纳入两性并探索不同PDE5I剂量的随机对照试验以确认关联。

研究设计与样本

  • 使用英国IQVIA医学研究数据(原THIN数据库)的电子健康记录开展队列研究。
  • 纳入2000至2017年新诊断勃起功能障碍的≥40岁男性,排除既往痴呆、认知障碍、意识模糊或曾处方痴呆症状药物者。
  • PDE5I启动作为时变暴露变量,采用基于倾向评分的逆概率治疗加权校正混杂,Cox比例风险模型估计校正HR及95%CI。
  • 敏感性分析设置队列进入后1年和3年滞后(延迟)期以处理阿尔茨海默病前驱期。

主要发现

  • 共纳入269,725例男性,中位随访5.1年(四分位距2.9-8.9年)期间1,119例新发阿尔茨海默病。
  • PDE5I启动者与非使用者相比,校正HR为0.82(95%CI 0.72-0.93)。
  • 处方21-50次者HR 0.56(95%CI 0.43-0.73),>50次者HR 0.65(95%CI 0.49-0.87)。
  • 1年滞后敏感性分析支持主分析结果,HR 0.82(95%CI 0.72-0.94)。
  • 3年滞后敏感性分析结果不同,HR 0.93(95%CI 0.80-1.08),未达统计学显著。

关键数值与推荐

  • PDE5I启动与非使用相比,阿尔茨海默病校正HR 0.82(95%CI 0.72-0.93)。
  • 处方21-50次者HR 0.56(95%CI 0.43-0.73),>50次者HR 0.65(95%CI 0.49-0.87)。
  • 1年滞后敏感性分析HR 0.82(95%CI 0.72-0.94),3年滞后HR 0.93(95%CI 0.80-1.08)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主分析与敏感性分析(3年滞后)结果存在差异,提示需探索最佳滞后时间。
  • 作者认为需纳入两性并探索不同PDE5I剂量的随机对照试验以确认关联并提高普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Repurposing phosphodiesterase type 5 inhibitors (PDE5Is) as drugs for Alzheimer disease (AD) risk reduction has shown promise based on animal studies. However, evidence in humans remains inconclusive. Therefore, we conducted a cohort study to evaluate the association between PDE5I initiation compared with nonuse and the risk of developing AD in men with erectile dysfunction (ED). METHODS: Using electronic health records from IQVIA Medical Research Data UK (formerly known as the THIN database), we identified men aged ≥40 years with a new diagnosis of ED between 2000 and 2017. Individuals with a previous diagnosis of dementia, cognitive impairment, confusion, or prescription for dementia symptoms were excluded. The occurrence of incident AD was identified using diagnostic read codes. To minimize immortal-time bias, PDE5I initiation was treated as a time-varying exposure variable. Potential confounders were adjusted using inverse probability of treatment weighting based on propensity scores. Cox proportional hazard models were used to estimate the adjusted hazard ratio (HR) with 95% CIs. A secondary analysis explored the association between AD and the cumulative number of PDE5I prescriptions. Sensitivity analyses included lag (delay) periods of 1 and 3 years after cohort entry to address the prodromal stage of AD. RESULTS: The study included 269,725 men, with 1,119 newly diagnosed with AD during a median follow-up of 5.1 (interquartile range 2.9-8.9) years. The adjusted HR in PDE5I initiators compared with nonuse was 0.82 (95% CI 0.72-0.93). The associated risk of AD decreased in individuals issued >20 prescriptions: HR 0.56 (95% CI 0.43-0.73) for 21-50 prescriptions and HR 0.65 (95% CI 0.49-0.87) for >50 prescriptions. Sensitivity analysis with a 1-year lag period supported the primary findings (HR 0.82, 95% CI 0.72-0.94), but the results differed with the inclusion of a 3-year lag period (HR 0.93, 95% CI 0.80-1.08). DISCUSSION: PDE5I initiation in men with ED was associated with a lower risk of AD, particularly in those most frequently issued prescriptions. The differences between primary and sensitivity analyses highlight the need to explore the optimal lag period. To enhance the generalizability of our findings, a randomized controlled trial including both sexes and exploring various PDE5I doses would be beneficial to confirm the association between PDE5I and AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Adesuyan M, Jani YH, Alsugeir D, et al. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study. Neurology. 2024. PMID: 38324745. doi:10.1212/WNL.0000000000209131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。